Hepatitis C viremic donors for hepatitis C nonviremic liver transplant recipients: Ready for prime time?
Elizabeth C. Verna, David S. Goldberg – 21 November 2017
Reply
Bruce Wang, Manisha Balwani, Herbert L. Bonkovsky, Karl E. Anderson, Joseph R. Bloomer, D. Montgomery Bissell, John D. Phillips, Robert J. Desnick, For the Porphyrias Consortium of the Rare Diseases Clinical Research Network – 21 November 2017
Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice
Edoardo Giovanni Giannini, Laura Bucci, Francesca Garuti, Matteo Brunacci, Barbara Lenzi, Matteo Valente, Eugenio Caturelli, Giuseppe Cabibbo, Fabio Piscaglia, Roberto Virdone, Martina Felder, Francesca Ciccarese, Francesco Giuseppe Foschi, Rodolfo Sacco, Gianluca Svegliati Baroni, Fabio Farinati, Gian Lodovico Rapaccini, Andrea Olivani, Antonio Gasbarrini, Maria Di Marco, Filomena Morisco, Marco Zoli, Alberto Masotto, Franco Borzio, Luisa Benvegnù, Fabio Marra, Antonio Colecchia, Gerardo Nardone, Mauro Bernardi, Franco Trevisani, for the Italian Liver Cancer (ITA.LI.CA) group – 21 November
Instructions to authors and Information for readers
20 November 2017
Notices
20 November 2017
Table of contents
20 November 2017
Longterm calcineurin inhibitor therapy and brain function in patients after liver transplantation
Henning Pflugrad, Anna‐Kristina Schrader, Anita Blanka Tryc, Xiaoqi Ding, Heinrich Lanfermann, Elmar Jäckel, Harald Schrem, Jan Beneke, Hannelore Barg‐Hock, Jürgen Klempnauer, Karin Weissenborn – 20 November 2017 – Calcineurin inhibitors (CNIs) frequently induce neurological complications early after orthotopic liver transplantation (OLT). We hypothesize that longterm CNI therapy after OLT causes dose‐dependent cognitive dysfunction and alteration of brain structure.
The role of genetics in hepatic fibrosis among hepatitis C virus patients
Heiyoung Park, Thomas R. O’Brien, Barbara Rehermann – 20 November 2017
Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV‐1 study
Cihan Yurdaydin, Onur Keskin, Çağdaş Kalkan, Fatih Karakaya, Aysun Çalişkan, Ersin Karatayli, Senem Karatayli, A. Mithat Bozdayi, Christopher Koh, Theo Heller, Ramazan Idilman, Jeffrey S. Glenn – 20 November 2017 – In a proof‐of‐concept (POC) study, the oral prenylation inhibitor, lonafarnib (LNF), decreased hepatitis D virus (HDV) RNA during 4 weeks of treatment. Here, we explored optimal LNF regimens.
Issue Information
20 November 2017